Shire Pharmaceuticals Group

LEXINGTON, Massachusetts, November 22, 2011 - Approval Will Add Substantial Manufacturing Capacity for Rare Disease Products Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted regulatory filings with both the European Medicines Agency (EMA) and the U.S.